Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22006159 | 1.00 | REN (0.43) | RENIDO1AGXTNAAANPC1 | |
| SCHEMBL31756570 | 0.81 | PDE4D (0.42) | — | |
| SCHEMBL23715175 | 0.75 | IDO1 (0.42) | RENIDO1AGXTNAAANPC1 | |
| SCHEMBL23704839 | 0.75 | IDO1 (0.42) | RENIDO1AGXTNAAANPC1 | |
| SCHEMBL30471210 | 0.74 | REN (0.42) | RENIDO1AGXTNAAASMN1; SMN2 | |
| SCHEMBL22006160 | 0.74 | REN (0.44) | RENIDO1AGXTNAAAKCNA5 | |
| SCHEMBL17803300 | 0.74 | REN (0.44) | RENIDO1AGXTNAAAKCNA5 | |
| SCHEMBL14180088 | 0.73 | TACR1 (0.48) | KCNA5 | |
| SCHEMBL24597253 | 0.73 | IDO1 (0.50) | RENIDO1AGXTNAAAKCNA5 | |
| SCHEMBL16821015 | 0.71 | REN (0.50) | RENIDO1AGXTNAAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3226690-B1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10086000-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | MERCK SHARP & DOHME CORP. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170362220-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170360800-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170360800-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362220-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3226690-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | Merck Sharp & Dohme Corp. (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-3226689-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | Merck Sharp & Dohme Corp. (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016089833-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089830-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089833-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089830-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362220-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | IDH3A, IDH3B, IDH2 | REN 1913/4885IDO1 550/4885AGXT 190/4885 |
| US-20170360800-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | IDH3A, IDH3B, IDH2 | REN 1800/4885IDO1 438/4885AGXT 214/4885 |
| US-10086000-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | IDH3A, IDH3B, IDH2 | REN 1764/4885IDO1 363/4885AGXT 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.